A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Bone marrow fibrosis is a central pathological feature and World Health Organization major
diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of …

Genetic and functional studies underscore the central role of JAK/STAT signaling in
myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate …

The 2016 revision of the World Health Organization (WHO) classification of
myeloproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF) …

Background Primary analyses of cohort 1a of the REFINE trial showed that addition of
navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR 35) and …

Abstract The recently published International Consensus Classification (ICC) of myeloid
neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and …

Clinical evidence supports the need of changing the diagnostic criteria of the 2008 updated
WHO classification for polycythemia vera (PV), essential thrombocythemia (ET) and primary …

Background Myelofibrosis (MF) is a life-shortening complication of myeloproliferative
neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone …

The grading of fibrosis in myeloproliferative neoplasms (MPN) is an important component of
disease classification, prognostication and monitoring. However, current fibrosis grading …

In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is
unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory …